EICHORPublic-registry trials using Ontunisertib that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Ontunisertib appears in 1 registered trial Eichor's radar has found, sponsored by Agomab Spain S.L.U., the most recent registered as Phase 2, with a planned enrollment of 320. Registered timeline: 2026–2028. The registry holds 8 registered studies for Fibrostenotic Crohn's Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease | Agomab Spain S.L.U. | Fibrostenotic Crohn's Disease | PHASE2 | 0 |
| Status | Not Yet Recruiting · planned start 2026-10 |
| Primary completion | 2028-12 |
| Enrollment target | 320 participants |
| Design | Randomized · Parallel · Phase 2 · 4 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | not yet posted — the record updates as sites are announced |
All fields verbatim from the ClinicalTrials.gov record for NCT07683325.
| First registered study | June 2026 — NCT07672574 (Agomab Spain S.L.U.) |
| Registered studies matching this name | 2 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 8 registered studies for Fibrostenotic Crohn's Disease. Compounds appearing:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Fibrostenotic Crohn's Disease studies · Weekly briefs
